Rigel Pharma (RIGL) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Rigel Pharmaceuticals (RIGL) PT Raised to $10 at BMO Capital Following Q1 Earnings Beat
May 2, 2018 1:12 AM EDTBMO Capital raised its price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $10.00 (from $8.00) while maintaining a Outperform rating.
Analyst Do Kim comments "We raise our estimates and target price to $10 from $8, as Rigel sets Tavalisse monthly WAC price at $9,450 or $113,400 annually,... More
